美国市场 - 相关文章

美国FDA、OTC、NDC化妆品申报认证行业资讯,助力企业合规出海

21 CFR Part 333 Subpart D—Topical Acne Drug Products

21 CFR Part 333 Subpart D—Topical Acne Drug ProductsSubpart D—Topical Acne Drug ProductsSource:56 FR 41019, Aug. 16, 1991, unless otherwise noted.§ 333.301 Scope.(a) An over-the-counter acne drug product in a form suitable for topical application is

21 CFR Part 358 Subpart B -- Wart Remover Drug Products

21 CFR Part 358 Subpart B -- Wart Remover Drug ProductsSubpart B—Wart Remover Drug Products§ 358.101 Scope.(a) An over-the-counter wart remover drug product in a form suitable for topical application is generally recognized as safe and effective and

21 CFR Part 358 Subpart D—Ingrown Toenail Relief Drug Products

21 CFR Part 358 Subpart D—Ingrown Toenail Relief Drug ProductsSubpart D—Ingrown Toenail Relief Drug ProductsSource:68 FR 24348, May 7, 2003, unless otherwise noted.§ 358.301 Scope.(a) An over-the-counter ingrown toenail relief drug product in a form

21 CFR Part 358 Subpart F—Corn and Callus Remover Drug Products

(a) An over-the-counter corn and callus remover drug product in a form suitable for topical application is generally recognized as safe and effective and is not misbranded if it meets each of the conditions in this subpart and each of the general conditions established in § 330.1 of this chapter.

指甲真菌液出口美国OTC注册指南:M005抗真菌专论与NDC登记全流程

2026年多家中国企业指甲真菌液产品通过FDA NDC注册进入美国市场。OTC专论M005允许7类活性成分用于抗真菌OTC药品,但适应症仅限足癣、股癣和体癣,未明确收录甲癣。企业须精准设计标签宣称,区分抑制真菌生长与治疗甲癣的合规边界,并完成FDA企业注册与NDC产品列名。